Pulmonx Corporation ( (LUNG) ) has released its Q1 earnings. Here is a breakdown of the information Pulmonx Corporation presented to its investors.
Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), offering innovative solutions like the Zephyr Endobronchial Valve to improve patient outcomes.
In its first quarter of 2025, Pulmonx Corporation reported a strong financial performance with a 20% increase in worldwide revenue, reaching $22.5 million. This growth was driven by a significant rise in both U.S. and international revenues, reflecting the company’s successful commercial strategies and global adoption of its Zephyr Valve procedures.
Key financial highlights include a 39% increase in international revenue and an 11% increase in U.S. revenue compared to the same period last year. Despite a slight decrease in gross margin from 75% to 73%, the company maintained a robust gross profit of $16.3 million. However, the net loss widened slightly to $14.4 million, attributed to increased operating expenses due to commercial investments.
Pulmonx also amended its loan agreement to extend the interest-only period, and the U.S. Department of Justice concluded its civil investigative demand without intervention. The company remains optimistic about its growth prospects, reaffirming its full-year revenue guidance between $96 million and $98 million.
Looking forward, Pulmonx’s management remains confident in its long-term growth strategy, focusing on expanding patient access to its treatments and maintaining its position as a leader in the COPD treatment market.